RBC Capital Markets has maintained its positive stance on Stryker Corporation (NYSE:SYK), reiterating an Outperform rating with a price target of $435.00. The firm's analyst highlighted Stryker's robust performance and outlook following a meeting with the company's top executives at the American Academy of Orthopaedic Surgeons (AAOS). Stryker's market capitalization stands at $139 billion, and the company has shown strong revenue growth of 10.2% in the last twelve months.

The article discusses the impact of recent trade policy changes, particularly tariffs, on major medtech companies. Intuitive Surgical and Boston Scientific have been especially affected due to their manufacturing and sourcing in Mexico and China. Medtronic, Johnson & Johnson, Stryker, and others have also seen stock performance decline due to the unpredictability of the Trump administration's tariff policies.

The 'Hip Replacement Market Report by Product, End-User, Regions and Company Analysis 2025-2033' report highlights the projected growth of the hip replacement market, reaching nearly US$10.24 billion by 2033. This growth is attributed to factors such as a growing older population, increasing cases of obesity, and advancements in surgical techniques and implant technology. The report also includes detailed company analyses of industry leaders like Smith & Nephew, J&J, Integra, Zimmer Biomet, Stryker, B. Braun Melsungen, Globus Medical, MicroPort Scientific, and Conformis.

Stryker Corporation (SYK) introduced the next-generation Mako SmartRobotics system at the American Academy of Orthopaedic Surgeons’ 2025 Annual Meeting, enhancing surgical precision and driving long-term growth. The company's stock fell 1.3% following the announcement, closing at $365.29. Stryker has expanded its Mako Total Hip offering and introduced the Mako 4, a consolidated robotics platform. Additionally, the company launched the Steri-Shield 8 personal protection system and the Sync Badge wearable communication device.

Ireland has emerged as a leader in the global MedTech sector, with approximately 450 companies employing over 45,000 people. The country's success is attributed to a unique ecosystem that has made it a preferred destination for MedTech companies. IDA Ireland has identified health as one of the four strategic growth drivers for investment, aiming to capitalize on opportunities within the MedTech sector. Stryker, a key player in Ireland's MedTech landscape, has been instrumental in driving innovation, particularly in 3D printing, and has partnerships with Cork University Hospital (CUH) and University College Cork (UCC) to advance medical technology.